Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	3.36B
Revenue (ttm)	754.65M
Net Income (ttm)	-228.17M
Shares Out	126.29M
EPS (ttm)	-1.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,381,795
Open	24.09
Previous Close	23.90
Day's Range	24.00 - 26.68
52-Week Range	16.10 - 41.94
Beta	0.77
Analysts	Buy
Price Target	34.11 (+28.33%)
Earnings Date	Jul 31, 2025

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 710
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://apellis.com

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.

Analyst Forecast

According to 20 analysts, the average rating for APLS stock is "Buy." The 12-month stock price target is $34.11, which is an increase of 28.33% from the latest price.

Price Target

$34.11

(28.33% upside)

Analyst Consensus: Buy